Zepbound produces significantly more weight loss than Wegovy. In a 72-week head-to-head clinical trial, people taking Zepbound lost an average of 20.2% of their body weight (about 50 pounds), while those on Wegovy lost 13.7% (about 33 pounds). That’s roughly 47% more weight loss with Zepbound, and the difference held up across other health markers too.
What the Head-to-Head Trial Found
Until recently, comparing these two drugs meant looking at separate clinical trials run at different times with different participants. That changed with SURMOUNT-5, a Phase 3b trial that directly randomized people with obesity (and without type 2 diabetes) to receive either Zepbound or Wegovy via weekly injection for 72 weeks.
The results were clear. Zepbound users lost an average of 20.2% of their starting body weight compared to 13.7% for Wegovy. Waist circumference dropped by 18.4 cm with Zepbound versus 13.0 cm with Wegovy. Both differences were statistically significant. These numbers align closely with earlier, separate trials: the SURMOUNT studies showed tirzepatide (Zepbound’s active ingredient) reduced body weight by 20.9% at maximum dose over 72 weeks, while the STEP trials showed semaglutide (Wegovy’s active ingredient) produced a 14.9% loss over 68 weeks.
Beyond weight, a post-hoc analysis of the same trial found that Zepbound reduced predicted 10-year cardiovascular disease risk by about 24% from baseline, compared to about 14% for Wegovy. That translated to an estimated 13% lower hazard of cardiovascular events for the Zepbound group relative to the Wegovy group after 72 weeks of treatment.
Why Zepbound Produces More Weight Loss
The key difference is in how many targets each drug hits. Wegovy activates one receptor in your body, called GLP-1, which slows digestion, reduces appetite, and helps regulate blood sugar. Zepbound activates that same receptor plus a second one called GIP. This dual action is why Zepbound is often described as a “dual agonist” while Wegovy is a “single agonist.”
The way Zepbound interacts with the GLP-1 receptor is also subtly different from how Wegovy does it. Research published in PNAS found that Zepbound binds to the GLP-1 receptor about five times more weakly than the body’s natural GLP-1 hormone, but this apparent weakness may actually be an advantage. It triggers less of the process where receptors become desensitized and stop responding as strongly over time. In practical terms, the GLP-1 component of Zepbound may maintain its effectiveness better with continued use, while the GIP component adds a separate, complementary pathway for appetite suppression and metabolic improvement.
Side Effects to Expect
Both drugs cause similar gastrointestinal side effects because they work through overlapping pathways. Nausea is the most common complaint with both medications, affecting roughly 44% of people on Wegovy, with diarrhea (30%) and vomiting (24%) also frequently reported. Zepbound’s side effect profile follows a similar pattern, with nausea, diarrhea, and vomiting being the most reported issues in clinical trials.
These side effects tend to be worst during the dose escalation phase and improve once your body adjusts. Both drugs use a gradual titration schedule specifically to minimize these problems. If you’re switching from one to the other, you may still experience GI symptoms as your body adapts to the new medication, even if you tolerated the previous one well.
How the Dosing Schedules Differ
Both medications are self-administered as a once-weekly subcutaneous injection (typically in the abdomen, thigh, or upper arm), and both start at a low dose that gradually increases over several months.
Zepbound starts at 2.5 mg weekly for the first four weeks, then increases to 5 mg. From there, the dose can go up in 2.5 mg steps every four weeks or longer, up to a maximum of 15 mg per week. Wegovy follows a five-step schedule: 0.25 mg for weeks one through four, 0.5 mg for weeks five through eight, 1 mg for weeks nine through twelve, 1.7 mg for weeks thirteen through sixteen, and then a maintenance dose of 1.7 or 2.4 mg from week seventeen onward.
In practice, it takes about 16 weeks to reach a maintenance dose on Wegovy. Zepbound’s timeline is more flexible since dose increases are optional at each step, but reaching the maximum 15 mg dose takes at least 20 weeks. Your prescriber will adjust the pace based on how well you tolerate each increase.
Cost and Availability
Both medications are expensive without insurance. Zepbound’s list price ranges from $499 to $1,086 per 28-day supply, depending on the dose. Wegovy’s retail price is about $1,349 per month. So at list price, Zepbound is generally less expensive, though what you actually pay depends heavily on your insurance plan, pharmacy, and any manufacturer savings programs.
Both drugs carry the same FDA eligibility criteria: they’re approved for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease. Insurance coverage varies widely, and many plans that cover one may not cover the other. Availability has also been an issue for both drugs, with periodic shortages affecting access.
Which One Is Right for You
On the numbers alone, Zepbound is the more effective weight loss medication. It produces about 50% more weight loss than Wegovy, costs less at list price, and shows a larger reduction in cardiovascular risk markers. For most people whose primary goal is maximum weight loss, the clinical evidence favors Zepbound.
That said, Wegovy has a longer track record. It was approved earlier, has more published long-term safety data, and has completed a large cardiovascular outcomes trial (SELECT) demonstrating a direct reduction in heart attacks and strokes. Zepbound’s cardiovascular outcomes trial is still ongoing. Some people also tolerate one medication better than the other, and insurance coverage or drug availability can be the deciding factor in practice. If you’ve already had good results on Wegovy, switching isn’t necessarily better for everyone, but the head-to-head data is hard to ignore if you’re choosing between the two for the first time.